CorriXR Therapeutics names Moorad as new CEO
Share
WILMINGTON – CorriXR Therapeutics, the gene-editing cancer drug firm spun out of ChristianaCare, has turned to Deborah Moorad, a biotech veteran who successfully grew and sold other firms, as its new chief executive. Founded by Dr. Eric Kmiec, who also heads ChristianaCare’s Gene Editing Institute and has been a leading national researcher in the use
Want to Read More?
Paid DBT subscribers get unlimited access to all Insider content and much more. Learn more in our Insider FAQ.
Already an Insider? Log In.